Britain’s medicine regulator has approved Johnson & Johnson’s COVID-19 vaccine for use, the health ministry says, making it the fourth COVID-19 shot available for use in the country.
Britain also cut its order for the single-dose shot, also known as J&J unit Janssen’s vaccine, amid issues with the company’s supply chain and reports of rare blood clots.
Britain has given two-thirds of the population a first dose of COVID-19, and the government cited the “unprecedented scale and pace” of the roll-out as behind the decision to cut its order to 20 million doses from the original order for 30 million doses.
“As Janssen is a single-dose vaccine, it will play an important role in the months to come as we redouble our efforts to encourage everyone to get their jabs and potentially begin a booster program later this year,” health minister Matt Hancock said.
J&J’s vaccine is already approved in the United States and European Union, where reports of rare blood clots are being reviewed.
The shot uses similar viral vector technology to the Oxford-AstraZeneca vaccine, where similar clots have been reported.
Britain has advised that under-40s are offered an alternative to the AstraZeneca shot, and the government said that vaccine advisers the Joint Committee on Vaccination and Immunisation (JCVI) would also advise on how J&J’s shot was used.
The government said the shot would be available later in the year. There have been reports that J&J expects to miss its delivery targets for the European Union this quarter.